Blmf, Lenalidomide and Dexamethasone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
Status:
Recruiting
Trial end date:
2027-02-22
Target enrollment:
Participant gender:
Summary
This is a phase 1/2, open label, study designed to assess the safety and clinical activity of
different Belantamab Mafodotin doses in combination with lenalidomide and dexamethasone.